Phase II study of extended-dose temozolomide in patients with melanoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Melanoma

abstract

  • Extended-dose TMZ therapy did not result in a 30% responses rate, which has been observed using extended-dose TMZ with antiangiogenic agents. Response did not correlate with MGMT expression or promoter methylation as a continuous variable, suggesting that other resistance mechanisms are important.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.14.5292

PubMed ID

  • 18467721

Additional Document Info

start page

  • 2299

end page

  • 304

volume

  • 26

number

  • 14